NSC666715 and Its analogs inhibit strand-displacement activity of DNA polymerase β and potentiate temozolomide-induced DNA damage, senescence and apoptosis in colorectal cancer cells

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Jaiswal, Aruna S ^a   Panda, Harekrushna ^b,d   Law, Brian K ^b   Sharma, Jay ^c   Jani, Jitesh ^c   Hromas, Robert ^a   Narayan, Satya ^b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c Celprogen Inc   (United States)

^d INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY ICGEB   (India)

Author keywords

[No Author keywords available]

Indexed keywords

2 [2 [(5 ANILINO 1H 1,2,4 TRIAZOL 3 YL)SULFAMOYL] 5 CHLORO 4 METHYLPHENYL]SULFANYLACETIC ACID; 4 CHLORO 5 METHYL N [5 (NAPHTHALEN 2 YLAMINO) 1H 1,2,4 TRIAZOL 3 YL] 2 SULFANYLBENZENESULFONAMIDE; 4 CHLORO N [5 (3 METHOXYANILINO) 1H 1,2,4 TRIAZOL 3 YL] 5 METHYL 2 SULFANYLBENZENESULFONAMIDE; 4 CHLORO N [5 (4 CHLOROANILINO) 1H 1,2,4 TRIAZOL 3 YL] 5 METHYL 2 SULFANYLBENZENESULFONAMIDE; ANTINEOPLASTIC AGENT; DNA; DNA DIRECTED DNA POLYMERASE BETA; N (5 ANILINO 1H 1,2,4 TRIAZOL 3 YL) 4 CHLORO 5 METHYL 2 SULFANYLBENZENESULFONAMIDE; PROTEIN P21; PROTEIN P53; TEMOZOLOMIDE; UNCLASSIFIED DRUG; BENZOTHIAZOLE DERIVATIVE; CYCLIN DEPENDENT KINASE INHIBITOR 1A; DACARBAZINE; ENZYME INHIBITOR; MOLECULAR LIBRARY; NSC666715; PIFITHRIN; SULFONAMIDE; THIOL DERIVATIVE; TOLUENE; TRIAZOLE DERIVATIVE;

APOPTOSIS; APURINIC SITE; APYRIMIDINIC SITE; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RESISTANCE; CELL AGING; COLORECTAL CANCER; CONTROLLED STUDY; DNA DAMAGE; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVITY; EXCISION REPAIR; HCT116 CELL LINE; HUMAN; HUMAN CELL; IC50; MOLECULAR DOCKING; S PHASE CELL CYCLE CHECKPOINT; SIGNAL TRANSDUCTION; ANALOGS AND DERIVATIVES; CELL CYCLE; CELL CYCLE CHECKPOINT; CHEMISTRY; COLORECTAL TUMOR; DNA REPAIR; DRUG EFFECTS; HCT 116 CELL LINE; METABOLISM; MOLECULAR LIBRARY; PATHOLOGY; PHARMACOLOGY;

APOPTOSIS; BENZOTHIAZOLES; CELL AGING; CELL CYCLE; CELL CYCLE CHECKPOINTS; COLORECTAL NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DACARBAZINE; DNA DAMAGE; DNA POLYMERASE BETA; DNA REPAIR; ENZYME INHIBITORS; HCT116 CELLS; HUMANS; SMALL MOLECULE LIBRARIES; SULFHYDRYL COMPOUNDS; SULFONAMIDES; TOLUENE; TRIAZOLES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84929081895     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0123808     Document Type: Article

References (61)

1. Kumar M, Nagpal R, Hemalatha R, Verma V, Kumar A, Singh S, et al. Targeted cancer therapies: the future of cancer treatment. Acta Biomed, 83(3): 220-33. PMID: 23762999
2. Savonarola A, Palmirotta R, Guadagni F, Silvestris F. Pharmacogenetics and pharmacogenomics: role of mutational analysis in anti-cancer targeted therapy. Pharmacogenomics J, 2012. 12(4): 277-86. doi: 10.1038/tpj.2012.28 PMID: 22760589
3. McWhirter D, Kitteringham N, Jones RP, Malik H, Park K, Palmer D. Chemotherapy induced hepatotoxicity in metastatic colorectal cancer: a review of mechanisms and outcomes. Crit Rev Oncol Hematol, 2013. 88(2): 404-15. doi: 10.1016/j.critrevonc.2013.05.011 PMID: 23786843
4. Marin JJ, Sanchez de Medina F, Castaño B, Bujanda L, Romero MR, Martinez-Augustin O, et al. Chemoprevention, chemotherapy, and chemoresistance in colorectal cancer. Drug Metab Rev, 2012. 44 (2): 148-72. doi: 10.3109/03602532.2011.638303 PMID: 22497631
5. Kaina B, Christmann M. DNA repair in resistance to alkylating anticancer drugs. Int J Clin Pharmacol Ther, 2002. 40(8): 354-67. PMID: 12467304
6. Longley DB, Allen WL, Johnston PG. Drug resistance, predictive markers and pharmacogenomics in colorectal cancer. Biochim Biophys Acta, 2006. 1766(2): 184-96. PMID: 16973289
7. Veuger SJ, Curtin NJ, Smith GC, Durkacz BW. Effects of novel inhibitors of poly(ADP-ribose) polymer-ase-1 and the DNA-dependent protein kinase on enzyme activities and DNA repair. Oncogene, 2004. 23(44): 7322-9. PMID: 15286704
8. Sawyers C. Targeted cancer therapy. Nature, 2004. 432(7015): 294-7. PMID: 15549090
9. Karran P and Bignami M. DNA damage tolerance, mismatch repair and genome instability. Bioessays, 1994. 16(11): 833-9. PMID: 7840761
10. Liu L, Markowitz S, Gerso SL. Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea. Cancer Res, 1996. 56(23):. 5375-9. PMID: 8968088
11. Denny BJ, Wheelhouse RT, Stevens MF, Tsang LL, Slack JA. NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA. Biochemistry, 1994. 33(31): 9045-51. PMID: 8049205
12. Tsang LL, Quarterman CP, Gescher A, Slack JA. Comparison of the cytotoxicity in vitro of temozolomide and dacarbazine, prodrugs of 3-methyl-(triazen-1-yl)imidazole-4-carboxamide. Cancer Chemother Pharmacol, 1991. 27(5): 342-6. PMID: 1998993
13. Liu L, Gerson SL. Therapeutic impact of methoxyamine: blocking repair of abasic sites in the base excision repair pathway. Curr Opin Investig Drugs, 2004. 5(6): 623-7. PMID: 15242251
14. Trivedi RN, Almeida KH, Fornsaglio JL, Schamus S, Sobol RW. The role of base excision repair in the sensitivity and resistance to temozolomide-mediated cell death. Cancer Res, 2005. 65(14): 6394-400. PMID: 16024643
15. Fishel ML, He Y, Smith ML, Kelley MR. Manipulation of base excision repair to sensitize ovarian cancer cells to alkylating agent temozolomide. Clin Cancer Res, 2007. 13(1): 260-7. PMID: 17200364
16. Kaina B, Christmann M, Naumann S, Roos WP. MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. DNA Repair (Amst), 2007. 6(8):. 1079-99. PMID: 17485253
17. Jaiswal AS, Banerjee S, Panda H, Bulkin CD, Izumi T, Sarkar FH, et al. A novel inhibitor of DNA polymerase beta enhances the ability of temozolomide to impair the growth of colon cancer cells. Mol Cancer Res, 2009. 7(12): 1973-83. doi: 10.1158/1541-7786.MCR-09-0309 PMID: 19996303
18. Liu L, Taverna P, Whitacre CM, Chatterjee S, Gerson SL. Pharmacologic disruption of base excision repair sensitizes mismatch repair-deficient and-proficient colon cancer cells to methylating agents. Clin Cancer Res, 1999. 5(10): 2908-17. PMID: 10537360
19. Fu D, Calvo JA, Samson LD. Balancing repair and tolerance of DNA damage caused by alkylating agents. Nat Rev Cancer, 2012. 12(2): 104-20. doi: 10.1038/nrc3185 PMID: 22237395
20. Venturelli S, Berger A, Weiland T, Essmann F, Waibel M, Nuebling T, et al. Differential induction of apoptosis and senescence by the DNA methyltransferase inhibitors 5-azacytidine and 5-aza-2'-deoxycytidine in solid tumor cells. Mol Cancer Ther, 2013. 12(10): 2226-36. doi: 10.1158/1535-7163.MCT-13-0137 PMID: 23924947
21. Jekimovs C, Bolderson E, Suraweera A, Adams M, O'Byrne KJ, Richard DJ. Chemotherapeutic Compounds Targeting the DNA Double-Strand Break Repair Pathways: The Good, the Bad, and the Promising. Front Oncol, 2014. 4: 86. doi: 10.3389/fonc.2014.00086 PMID: 24795863
22. Günther W, Pawlak E, Damasceno R, Arnold H, Terzis AJ. Temozolomide induces apoptosis and senescence in glioma cells cultured as multicellular spheroids. Br J Cancer, 2003. 88(3): 463-9. PMID: 12569392
23. Das A, Banik NL, Patel SJ, Ray SK. Dexamethasone protected human glioblastoma U87MG cells from temozolomide induced apoptosis by maintaining Bax:Bcl-2 ratio and preventing proteolytic activities. Mol Cancer, 2004. 3(1): 36. PMID: 15588281
24. Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest, 1999. 104(3): 263-9. PMID: 10430607
25. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science, 1998. 282(5393): 1497-501. PMID: 9822382
26. Narayan S, Jaiswal AS, Balusu R. Tumor suppressor APC blocks DNA polymerase beta-dependent strand displacement synthesis during long patch but not short patch base excision repair and increases sensitivity to methylmethane sulfonate. J Biol Chem, 2005. 280(8):. 6942-9. PMID: 15548520
27. Jaiswal AS, Banerjee S, Aneja R, Sarkar FH, Ostrov DA, Narayan S. DNA polymerase beta as a novel target for chemotherapeutic intervention of colorectal cancer. PLoS One, 2011. 6(2): e16691. doi: 10.1371/journal.pone.0016691 PMID: 21311763
28. Jaiswal AS, Balusu R, Armas ML, Kundu CN, Narayan S. Mechanism of adenomatous polyposis coli (APC)-mediated blockage of long-patch base excision repair. Biochemistry, 2006. 45(51): 15903-14. PMID: 17176113
29. Balusu R, Jaiswal AS, Armas ML, Kundu CN, Bloom LB, Narayan S. Structure/function analysis of the interaction of adenomatous polyposis coli with DNA polymerase beta and its implications for base excision repair. Biochemistry, 2007. 46(49): 13961-74. PMID: 17999539
30. Nakamura J, Walker VE, Upton PB, Chiang SY, Kow YW, Swenberg JA. Highly sensitive apurinic/apyrimidinic site assay can detect spontaneous and chemically induced depurination under physiological conditions. Cancer Res, 1998. 58(2): 222-5. PMID: 9443396
31. Jaiswal AS, Panda H, Pampo CA, Siemann DW, Gairola CG, Hromas R, et al. Adenomatous polyposis coli-mediated accumulation of abasic DNA lesions lead to cigarette smoke condensate-induced neoplastic transformation of normal breast epithelial cells. Neoplasia, 2013. 15(4): 454-60. PMID: 23555190
32. Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A, 1995. 92(20): 9363-7. PMID: 7568133
33. Itahana K, Itahana Y, Dimri GP. Colorimetric detection of senescence-associated beta galactosidase. Methods Mol Biol, 2013. 965: 143-56. doi: 10.1007/978-1-62703-239-1-8 PMID: 23296655
34. Jaiswal AS, Multani AS, Pathak S, Narayan S. N-methyl-N'-nitro-N-nitrosoguanidine-induced senescence- like growth arrest in colon cancer cells is associated with loss of adenomatous polyposis coli protein, microtubule organization, and telomeric DNA. Mol Cancer, 2004. 3: 3. PMID: 14728717
35. Martinkova E, Maglott A, Leger DY, Bonnet D, Stiborova M, Takeda K. alpha5beta1 integrin antagonists reduce chemotherapy-induced premature senescence and facilitate apoptosis in human glioblastoma cells. Int J Cancer, 2010. 127(5): 1240-8. doi: 10.1002/ijc.25187 PMID: 20099278
36. Jaiswal AS, Marlow BP, Gupta N, Narayan S. Beta-catenin-mediated transactivation and cell-cell adhesion pathways are important in curcumin (diferuylmethane)-induced growth arrest and apoptosis in colon cancer cells. Oncogene, 2002. 21(55): 8414-27. PMID: 12466962
37. Prasad R, Dianov GL, Bohr VA, Wilson SH. FEN1 stimulation of DNA polymerase beta mediates an excision step in mammalian long patch base excision repair. J Biol Chem, 2000. 275(6): 4460-6. PMID: 10660619
38. Prasad R, Lavrik OI, Kim SJ, Kedar P, Yang XP, Vande Berg BJ, et al., DNA polymerase beta-mediated long patch base excision repair. Poly(ADP-ribose)polymerase-1 stimulates strand displacement DNA synthesis. J Biol Chem, 2001. 276(35): 32411-4. PMID: 11440997
39. Komarov PG, Komarova EA, Kondratov RV, Christov-Tselkov K, Coon JS, Chernov MV, et al. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science, 1999. 285 (5434): p. 1733-7. PMID: 10481009
40. Sur S, Pagliarini R, Bunz F, Rago C, Diaz LA Jr, Kinzler KW, et al. A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53. Proc Natl Acad Sci U S A, 2009. 106(10): 3964-9. doi: 10.1073/pnas.0813333106 PMID: 19225112
41. Sevrioukova IF. Apoptosis-inducing factor: structure, function, and redox regulation. Antioxid Redox Signal, 2011. 14(12): 2545-79. doi: 10.1089/ars.2010.3445 PMID: 20868295
42. Cohen MH, Johnson JR, Pazdur R. Food and Drug Administration Drug approval summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme. Clin Cancer Res, 2005. 11(19 Pt 1): 6767-71. PMID: 16203762
43. Spiro TP, Liu L, Majka S, Haaga J, Willson JK, Gerson SL. Temozolomide: the effect of once- and twice-a-day dosing on tumor tissue levels of the DNA repair protein O(6)-alkylguanine-DNA-alkyltransferase. Clin Cancer Res, 2001. 7(8): 2309-17. PMID: 11489806
44. Khan OA, Ranson M, Michael M, Olver I, Levitt NC, Mortimer P, et al. A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancer. Br J Cancer, 2008. 98(10): 1614-8. doi: 10.1038/sj.bjc.6604366 PMID: 18475294
45. Ma W, Westmoreland JW, Gordenin DA, Resnick MA. Alkylation base damage is converted into repairable double-strand breaks and complex intermediates in G2 cells lacking AP endonuclease. PLoS Genet, 2011. 7(4): e1002059. doi: 10.1371/journal.pgen.1002059 PMID: 21552545
46. Knizhnik AV, Roos WP, Nikolova T, Quiros S, Tomaszowski KH, Christmann M, et al. Survival and death strategies in glioma cells: autophagy, senescence and apoptosis triggered by a single type of temozolomide-induced DNA damage. PLoS One, 2013. 8(1): e55665. doi: 10.1371/journal.pone.0055665 PMID: 23383259
47. Kawate H, Sakumi K, Tsuzuki T, Nakatsuru Y, Ishikawa T, Takahashi S, et al. Separation of killing and tumorigenic effects of an alkylating agent in mice defective in two of the DNA repair genes. Proc Natl Acad Sci U S A, 1998. 95(9): 5116-20. PMID: 9560238
48. Branch P, Aquilina G, Bignami M, Karran P. Defective mismatch binding and a mutator phenotype in cells tolerant to DNA damage. Nature, 1993. 362(6421): 652-4. PMID: 8464518
49. Tentori L, Lacal PM, Benincasa E, Franco D, Faraoni I, Bonmassar E. Role of wild-type p53 on the antineoplastic activity of temozolomide alone or combined with inhibitors of poly(ADP-ribose) polymerase. J Pharmacol Exp Ther, 1998. 285(2): 884-93. PMID: 9580640
50. Schmitt CA. Senescence, apoptosis and therapy-cutting the lifelines of cancer. Nat Rev Cancer, 2003. 3(4): 286-95. PMID: 12671667
51. Gewirtz DA, Holt SE, Elmore LW. Accelerated senescence: an emerging role in tumor cell response to chemotherapy and radiation. Biochem Pharmacol, 2008. 76(8): 947-57. doi: 10.1016/j.bcp.2008.06.024 PMID: 18657518
52. Muller M. Cellular senescence: molecular mechanisms, in vivo significance, and redox considerations. Antioxid Redox Signal, 2009. 11(1): 59-98. doi: 10.1089/ars.2008.2104 PMID: 18976161
53. Kuilman T, Michaloglou C, Mooi WJ, Peeper DS. The essence of senescence. Genes Dev, 2010. 24 (22): 2463-79. doi: 10.1101/gad.1971610 PMID: 21078816
54. Collado M, Blasco MA, Serrano M. Cellular senescence in cancer and aging. Cell, 2007. 130(2): 223-33. PMID: 17662938
55. Weizman N, Shiloh Y, Barzilai A. Contribution of the Atm protein to maintaining cellular homeostasis evidenced by continuous activation of the AP-1 pathway in Atm-deficient brains. J Biol Chem, 2003. 278 (9): 6741-7. PMID: 12496286
56. von Zglinicki T, Saretzki G, Ladhoff J, d'Adda di Fagagna F, Jackson SP. Human cell senescence as a DNA damage response. Mech Ageing Dev, 2005. 126(1): 111-7. PMID: 15610769
57. Hayashi T, Adachi K, Ohba S, Hirose Y. The Cdk inhibitor flavopiridol enhances temozolomide-induced cytotoxicity in human glioma cells. J Neurooncol, 2013. 115(2): 169-78. doi: 10.1007/s11060-013-1220-5 PMID: 23943501
58. O'Connell MJ, Walworth NC, Carr AM. The G2-phase DNA-damage checkpoint. Trends Cell Biol, 2000. 10(7): 296-303. PMID: 10856933
59. Hirose Y, Katayama M, Mirzoeva OK, Berger MS, Pieper RO. Akt activation suppresses Chk2-mediated, methylating agent-induced G2 arrest and protects from temozolomide-induced mitotic catastrophe and cellular senescence. Cancer Res, 2005. 65(11): 4861-9. PMID: 15930307
60. Narayan S, Jaiswal AS, Multani AS, Pathak S. DNA damage-induced cell cycle checkpoints involve both p53-dependent and-independent pathways: role of telomere repeat binding factor 2. Br J Cancer, 2001. 85(6): 898-901. PMID: 11556843
61. Gupte M, Tuck AN, Sharma VP, Williams KJ. Major differences between tumor and normal human cell fates after exposure to chemotherapeutic monofunctional alkylator. PLoS One, 2013. 8(9): p. e74071. doi: 10.1371/journal.pone.0074071 PMID: 24019948